Quantifying the therapeutic requirements and potential for combination therapy to prevent bacterial coinfection during influenza

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 44, Issue 2, 2017, Pages 81-93

  Smith, Amber M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antibiotics; Antivirals; Coinfection; Combination therapy; Immunotherapy; Influenza; Kinetic modeling; Pneumococcus

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CLINDAMYCIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL KINETICS; BACTERIAL LOAD; DISEASE SEVERITY; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLUENZA; MIXED INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; VIRAL CLEARANCE; VIROGENESIS; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BACTERIAL INFECTIONS; BAGG ALBINO MOUSE; COINFECTION; FEMALE; MICROBIOLOGY; MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; VIROLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; COINFECTION; FEMALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84988689800     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-016-9494-9     Document Type: Article

References (48)

1. Aoki F, Macleod M, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, Ward P, IMPACT Study Group, et al (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51(1):123–129
2. Baccam P, Beauchemin C, Macken C, Hayden F, Perelson A (2006) Kinetics of influenza A virus infection in humans. J Virol 80(15):7590–7599
3. Brundage J, (2006) Interactions between influenza and bacterial respiratory pathogens: Implications for pandemic preparedness. Lancet Infect Dis 6(5):303–312
4. Chien Y, Klugman K, Morens D (2009) Bacterial pathogens and death during the 1918 influenza pandemic. New Engl J Med 361(26):2582–2583
5. Colamussi M, White M, Crouch E, Hartshorn K (1999) Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Blood 93(7):2395–2403
6. Engelich G, White M, Hartshorn K (2001) Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcuspneumoniae: Role of respiratory burst. J Leukoc Biol 69:50–56
7. Ghoneim H, McCullers J (2014) Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. J Infect Dis 209(9):1459–1468. doi:10.1093/infdis/jit653
8. Ghoneim H, Thomas P, McCullers J (2013) Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 191(3):1250–1259
9. Gubareva L, Kaiser L, Hayden F (2000) Influenza virus neuraminidase inhibitors. Lancet 355(9206):827–835
10. Hamilton J (2008) Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8(7):533–544
11. Hayden FG (2013) Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 7(s1):63–75
12. Karlström Å, Boyd K, English B, McCullers J (2009) Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 199(3):311–319
13. Karlström Å, Heston S, Boyd K, Tuomanen E, McCullers J (2011) Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 204(9):1358–1366
14. Kobayashi S, Braughton K, Whitney A, Voyich J, Schwan T, Musser J, DeLeo F (2003) Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. P Natl Acad Sci USA 100(19):10948–10953
15. Li R, Lim A, Phoon M, Narasaraju T, Ng J, Poh W, Sim M, Chow V, Locht C, Alonso S (2010) Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. J Virol 84(14):7105–7113
16. Liu X, He Y, Xiao K, White J, Fusco D, Papanicolaou G (2013) Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfection. PloS One 8(3):e57483
17. Louria D, Blumenfeld H, Ellis J, Kilbourne E, Rogers D (1959) Studies on influenza in the pandemic of 1957–1958. II. Pulmonary complications of influenza. J Clin Investig 38(1 Pt 1-2):213–265
18. McCullers J (2004) Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 190(3):519–526
19. McCullers J (2011) Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 16(2):123–135
20. McCullers J (2014) The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 12(4):252–262
21. McCullers J, Bartmess K (2003) Role of neuraminidase in lethal synergism between influenza virus and Streptococcuspneumoniae. J Infect Dis 187(6):1000–1009
22. McCullers J, Rehg J (2002) Lethal synergism between influenza virus and Streptococcuspneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 186(3):341–350
23. McNamee L, Harmsen A (2006) Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcuspneumoniae infection. Infect Immun 74(12):6707–6721
24. Metzger D, Sun K (2013) Immune dysfunction and bacterial coinfections following influenza. J Immunol 191(5):2047–2052
25. Metzger D, Furuya Y, Salmon S, Roberts S, Sun K (2015) Limited efficacy of antibacterial vaccination against secondary serotype 3 pneumococcal pneumonia following influenza infection. J Infect Dis 212(3):445–452
26. Mifsud E, Tan A, Short K, Brown L, Chua B, Jackson D (2016) Reducing the impact of influenza-associated secondary pneumococcal infections. Immunol Cell Biol 94(1):101–108
27. Mina M, Klugman K, McCullers J (2013) LAIV, but not PCV, protects against increased density and duration of pneumococcal carriage following influenza infection in pneumococcal colonized mice. J Infect Dis 208(8): 1281–1285 (p jit317)
28. Mina M, Brown L, Klugman K (2015) Dynamics of increasing IFN- γ exposure on murine MH-S cell-line alveolar macrophage phagocytosis of Streptococcuspneumoniae. J Interf Cytok Res 35(6):474–479
29. Morens D, Taubenberger J, Fauci A (2008) Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198(7):962–970
30. Peltola V, McCullers J (2004) Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis 23(1, Supplement): S87–S97
31. Plot digitizer. URL http://plotdigitizer.sourceforge.net/
32. Reed C, Chaves S, Kirley P, Emerson R, Aragon D, Hancock E, Butler L, Baumbach J, Hollick G, Bennett N, et al (2015) Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One 10(3):e0118,369
33. Robinson K, Kolls J, Alcorn J (2015) The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol 34:59–67
34. Rynda-Apple A, Robinson K, Alcorn J (2015) Influenza and bacterial superinfection: illuminating the immunologic mechanisms of disease. Infect Immun 83(10):3764–3770
35. Short K, Habets M, Hermans P, Diavatopoulos D (2012) Interactions between Streptococcuspneumoniae and influenza virus: a mutually beneficial relationship? Future Microbiol 7(5):609–624
36. Small C, Shaler C, McCormick S, Jeyanathan M, Damjanovic D, Brown E, Arck P, Jordana M, Kaushic C, Ashkar A et al (2010) Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol 184(4):2048–2056
37. Smith A, McCullers J (2014) Secondary bacterial infections in influenza virus infection pathogenesis. In: Influenza pathogenesis and control-volume I, Springer, New York, pp 327–356
38. Smith A, Smith A (2016) A critical, nonlinear threshold dictates bacterial invasion and initial kinetics during influenza. bioRxiv p 052175
39. Smith M, Schmidt J, Rehg J, Orihuela C, McCullers J (2007) Induction of pro-and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med 57(1):82–89
40. Smith A, Adler F, Perelson A (2010) An accurate two-phase approximate solution to an acute viral infection model. J Math Biol 60(5):711–726
41. Smith A, Adler F, McAuley J, Gutenkunst R, Ribeiro R, McCullers J, Perelson A (2011a) Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. PLoS Comput Biol 7(2):e1001081
42. Smith A, McCullers J, Adler F (2011b) Mathematical model of a three-stage innate immune response to a pneumococcal lung infection. J Theor Biol 276(1):106–116. doi:10.1016/j.jtbi.2011.01.052
43. Smith A, Adler F, Ribeiro R, Gutenkunst R, McAuley J, McCullers J, Perelson A (2013) Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 9(3):e1003238–e1003238
44. Sun K, Metzger D (2008) Inhibition of pulmonary antibacterial defense by interferon- γ during recovery from influenza infection. Nat Med 14(5):558–564
45. Thompson W, Shay D, Weintraub E, Brammer L, Cox Bridges N CB, Fukuda K (2004) Influenza-associated hospitalizations in the United States. J Am Med Assoc 292(11):1333–1340
46. Warnking K, Klemm C, Löffler B, Niemann S, Krüchten A, Peters G, Ludwig S, Ehrhardt C (2015) Super-infection with Staphylococcusaureus inhibits influenza virus-induced type I IFN signalling through impaired STAT1-STAT2 dimerization. Cell Microbiol 17(3):303–317
47. Weeks-Gorospe J, Hurtig H, Iverson A, Schuneman M, Webby R, McCullers J, Huber V (2012) Naturally occurring swine influenza A virus PB1-F2 phenotypes that contribute to superinfection with gram-positive respiratory pathogens. J Virol 86(17):9035–9043
48. Weinberger D, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C (2012) Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis 205(3):458–465